FDA Review of Schwarz’s Neupro Shaped By Parkinson’s Pharmacovigilance
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s review of the Schwarz Neupro (rotigotine) NDA illustrates the important role pharmacovigilance has come to play in the agency’s consideration of new Parkinson’s disease treatments.